Brian C. Davis, M.D., and Amit G. Singal, M.D., M.S.
Dr. Davis Is Resident Physician and Dr. Singal is Associate Professor, Medical Director of Liver Tumor Program, Department of Internal Medicine, Division of Digestive and Liver Diseases, University of Texas Southwestern Medical Center, Dallas, TX.
Within the past 12 months, Dr Davis has no conflicts of interest relevant to this activity. Dr. Singal is on the speaker’s bureau for Bayer, consulted for Bayer and Wako Diagnostics and has received research support from Gilead.
Albert Einstein College of Medicine, CCME staff, and interMDnet staff have nothing to disclose relevant to this activity.
Estimated time to complete:
Albert Einstein College of Medicine – Montefiore Medical Center designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™.
Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In support of improving patient care, this activity has been planned and implemented by Albert Einstein College of Medicine-Montefiore Medical Center and InterMDnet. Albert Einstein College of Medicine – Montefiore Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Upon completion of this Cyberounds®
, you should be able to:
- List and discuss effective methods for prevention and early detection of HCC in patients with cirrhosis;
- Recommend treatment options for patients with cirrhosis and HCC at all stages – early stage, intermediate stage, advanced stage, and terminal stage;
- Integrate the role of multidisciplinary care for treatment of patients with HCC.